Sanofi says it has reached an agreement with Dren Bio that would see it take control of autoimmune disease treatment DR-0201, a bispecific antibody-based myeloid cell engager with the potential to ...

What an amazing day for Dren Bio! I couldn’t be more proud of the top-notch team we have and the groundbreaking science that is happening here every day. So grateful to have been part of the ...

Merida is working on a selective therapy for Graves’ disease, leveraging targeted therapies that can deplete disease-causing ...

（2025西派会将于5月9-10日在广州举办，顶尖智慧共聚，帮助广大临床医生更好把握AI+医疗的未来趋势和技术应用，大会现正火热报名中。）2025年3月，生物制药公司加速了在小分子药物、双特异性抗体和蛋白治疗药物等领域的药物开发。阿斯利康和诺和诺德是 ...

In a bid to pursue growing sales, Sanofi doubled down on investing in immunology with the $600 million upfront buyout of Dren Bio’s clinical stage bispecific antibody. The antibody has been evaluated ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Financing of Merida Biosciences was backed by Bain Capital Life Sciences, BVF Partners and Third Rock Ventures, with participation from multiple other investors. Merida Biosciences announced that it ...

The Challenges of Market Access in Europe that Pharma Companies Face: Q&A with Mike Ryan ...

Apr. 10, 2025 — Bioinformaticians have established that the genes in bacterial genomes are arranged in a meaningful order. They describe that the genes are arranged by function: If they become ...

The first lawsuit claiming that gastrointestinal drug Zantac causes cancer has been voluntarily dismissed a week before it was due to come to trial, in an early victory for the pharma companies ...